The making of bispecific antibodies
暂无分享,去创建一个
[1] R. V. van Ginkel,et al. Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. , 2016, The Journal of investigative dermatology.
[2] M. Little,et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells , 2014, mAbs.
[3] W. Sandoval,et al. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity , 2013, mAbs.
[4] Sahana Bose,et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. , 2009, mAbs.
[5] P. Parren,et al. The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcγRI and FcγRIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A1 , 2000, The Journal of Immunology.
[6] C. Sheridan. Amgen's bispecific antibody puffs across finish line , 2015, Nature Biotechnology.
[7] P. Moore,et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.
[8] Tilman Schlothauer,et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies , 2014, mAbs.
[9] Wolfgang Schaefer,et al. The use of CrossMAb technology for the generation of bi- and multispecific antibodies , 2016, mAbs.
[10] Jason M. Edmonds,et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery , 2013, mAbs.
[11] S. Tsao,et al. Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor , 2013, Molecular Cancer Therapeutics.
[12] J. Huston,et al. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region. , 1996, Biophysical journal.
[13] M. Ravic,et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. , 2011, Blood.
[14] L. Williamson,et al. Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities , 1999, European journal of immunology.
[15] W. Pardridge,et al. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies , 2016, Expert opinion on biological therapy.
[16] P F Davison,et al. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. , 1985, Science.
[17] F. Szoka,et al. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. , 2015, Advanced drug delivery reviews.
[18] Paul J Conroy,et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications , 2013, Trends in Biotechnology.
[19] S. Thierfelder,et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.
[20] C. Hannum,et al. ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.
[21] Naoko Yamane-Ohnuki,et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. , 2006, Journal of biochemistry.
[22] Gregory J. Chen,et al. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma. , 2016, Biochemical and biophysical research communications.
[23] Ulrik B. Nielsen,et al. Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.
[24] F. Breitling,et al. Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli. , 2000, Protein engineering.
[25] D. Goldenberg,et al. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy , 2014, mAbs.
[26] Juan Ma,et al. Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody , 2013, PloS one.
[27] Alain Dupuy,et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications , 2016, mAbs.
[28] T. Logtenberg,et al. Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library (*) , 1996, The Journal of Biological Chemistry.
[29] Yong-Sung Kim,et al. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation. , 2015, Molecular immunology.
[30] Peter M Tessier,et al. Advances in Antibody Design. , 2015, Annual review of biomedical engineering.
[31] J. Miller,et al. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells , 2016, Targeted Oncology.
[32] L. Presta,et al. Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.
[33] L. Lum,et al. Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model , 2004, Cancer.
[34] P. Parren,et al. Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy? , 2016, Current opinion in immunology.
[35] J. V. D. van de Winkel,et al. Immunotherapeutic perspective for bispecific antibodies. , 2000, Immunology today.
[36] Y. Kim,et al. Bispecific Her2 × cotinine antibody in combination with cotinine–(histidine)2–iodine for the pre-targeting of Her2-positive breast cancer xenografts , 2014, Journal of Cancer Research and Clinical Oncology.
[37] Louis M. Weiner,et al. Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format* , 2004, Journal of Biological Chemistry.
[38] B. Jakobsen,et al. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells , 2014, Cancer Immunology, Immunotherapy.
[39] J. Byrd,et al. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. , 2012, Blood.
[40] R. Giovannini,et al. BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs , 2013, BMC Proceedings.
[41] Jennie W. Taylor,et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016, Proceedings of the National Academy of Sciences.
[42] R. Kontermann,et al. Humanization of a Mouse Monoclonal Antibody Directed Against a Cell Surface-Exposed Epitope of Membrane-Associated Heat Shock Protein 70 (Hsp70) , 2010, Molecular biotechnology.
[43] O. Stremovskiy,et al. Expression of single-chain antibody-barstar fusion in plants. , 2007, Biochimie.
[44] J. Guenot,et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia , 2016, Clinical Cancer Research.
[45] P. He,et al. A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells , 2016, AMB Express.
[46] Andreas Plückthun,et al. Design of multivalent complexes using the barnase·barstar module , 2003, Nature Biotechnology.
[47] Zhen-ping Zhu,et al. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. , 2007, Journal of immunological methods.
[48] R. Kontermann,et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice , 2016, mAbs.
[49] R. Kelley,et al. High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity , 2011, PloS one.
[50] A. Ali,et al. scFv Antibody: Principles and Clinical Application , 2012, Clinical & developmental immunology.
[51] G. Fuh,et al. A Two-in-One antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions , 2014, mAbs.
[52] R. Kontermann,et al. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.
[53] Chengbin Wu. Diabodies: molecular engineering and therapeutic applications. , 2009, Drug news & perspectives.
[54] S. Brack,et al. A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action , 2014, Molecular Cancer Therapeutics.
[55] M. Fanger,et al. Bispecific antibodies. , 1992, Critical reviews in immunology.
[56] T. Ghayur,et al. Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities , 2014, PloS one.
[57] C. Klein,et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. , 2012, Archives of biochemistry and biophysics.
[58] P. Kufer,et al. A revival of bispecific antibodies. , 2004, Trends in biotechnology.
[59] Leslie R Evans,et al. Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.
[60] Jian Yu,et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity , 2016, Cell.
[61] D. Chelius,et al. Structural and functional characterization of the trifunctional antibody catumaxomab , 2010, mAbs.
[62] Min-Yuan Chou,et al. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors , 2016, Theranostics.
[63] P. Carter,et al. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. , 1998, Biochemistry.
[64] D. Schmidt,et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. , 2014, The Journal of infectious diseases.
[65] U. Brinkmann,et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing , 2012, Protein engineering, design & selection : PEDS.
[66] A. Spriel,et al. Immunotherapeutic perspective for bispecific antibodies. , 2000 .
[67] Dongmei He,et al. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies , 2015, mAbs.
[68] D. Zaller,et al. IgG2m4, an engineered antibody isotype with reduced Fc function , 2009, mAbs.
[69] A. Plückthun,et al. New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.
[70] Sarah Batey,et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases , 2015, mAbs.
[71] Sally E. Ward,et al. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells , 2013, mAbs.
[72] Camellia W. Adams,et al. An efficient route to human bispecific IgG , 1998, Nature Biotechnology.
[73] L. Croner,et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. , 2010, Protein engineering, design & selection : PEDS.
[74] Zhen-ping Zhu,et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation , 2015, mAbs.
[75] R. Williams,et al. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. , 1996, Protein engineering.
[76] S. Larson,et al. Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex , 2014, Molecular Cancer Therapeutics.
[77] R. Kontermann,et al. Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region , 1999, FEBS letters.
[78] D. Nagorsen,et al. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer , 2015, Expert opinion on biological therapy.
[79] Carsten Reinhardt,et al. Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.
[80] Werner Scheuer,et al. TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations , 2016, Protein engineering, design & selection : PEDS.
[81] Eugene A Zhukovsky,et al. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. , 2016, Current opinion in immunology.
[82] John Calvin Reed,et al. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death , 2015, Molecular Cancer Therapeutics.
[83] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[84] John Kelly,et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability , 2013, mAbs.
[85] Pavel Strop,et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.
[86] P. Parren,et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1 , 2014, Nature Protocols.
[87] Christian Obinger,et al. Engineered IgG1‐Fc – one fragment to bind them all , 2016, Immunological reviews.
[88] Zhen-ping Zhu,et al. An efficient route to the production of an IgG-like bispecific antibody. , 2000, Protein engineering.
[89] D. Kranz,et al. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. , 1994, Journal of immunology.
[90] C. Obinger,et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. , 2013, Protein engineering, design & selection : PEDS.
[91] D. Goldenberg,et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. , 2009, Blood.
[92] C. Klein,et al. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry , 2016, mAbs.
[93] G. Adams,et al. Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity1 , 2001, Journal of Immunology.
[94] D. Curiel,et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. , 2003, Vaccine.
[95] C. Milstein,et al. Bispecific monoclonal antibodies from hybrid hybridomas. , 1986, Methods in enzymology.
[96] M. Mack,et al. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer , 1997, Cancer Immunology, Immunotherapy.
[97] B. Robert,et al. Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells , 2013, Molecular Cancer Therapeutics.
[98] D. Goldenberg,et al. Complex and defined biostructures with the dock-and-lock method. , 2012, Trends in pharmacological sciences.
[99] G. Schaefer,et al. LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies* , 2012, The Journal of Biological Chemistry.
[100] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[101] P. Harari,et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. , 2013, Cancer research.
[102] R. Kontermann,et al. Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.
[103] M. Bonten,et al. The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[104] I. Pastan,et al. Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments , 1996, Nature Biotechnology.
[105] M. Sliwkowski,et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.
[106] Herren Wu,et al. Insights into the molecular basis of a bispecific antibody's target selectivity , 2015, mAbs.
[107] Franklin Peale,et al. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.
[108] Wei Zhao,et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa , 2014, Science Translational Medicine.
[109] C. Jakob,et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule , 2013, mAbs.
[110] Yang Yang,et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. , 2015, Cancer research.
[111] R. Woods,et al. LC-MS characterization and purity assessment of a prototype bispecific antibody , 2013, mAbs.
[112] J. Buchner,et al. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies , 2016, mAbs.
[113] Jinjing Wang,et al. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR , 2015, Journal of Cancer Research and Clinical Oncology.
[114] Junho Chung,et al. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification , 2013, Experimental & Molecular Medicine.
[115] Sahana Bose,et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.
[116] R. Kontermann,et al. Complement recruitment using bispecific diabodies , 1997, Nature Biotechnology.
[117] Yves Poitevin,et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG , 2015, Nature Communications.
[118] S. Kanner,et al. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes. , 1998, International immunology.
[119] P. Carter,et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.
[120] Zhen-ping Zhu,et al. Single Variable Domain-IgG Fusion , 2006, Journal of Biological Chemistry.
[121] U. Brinkmann,et al. Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains , 2011, Antimicrobial Agents and Chemotherapy.
[122] Soila Sukupolvi-Petty,et al. Protection by Immunoglobulin Dual-Affinity Retargeting Antibodies against Dengue Virus , 2013, Journal of Virology.
[123] Christilyn P. Graff,et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity , 2011, mAbs.
[124] Peter Bohlen,et al. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. , 2002, Journal of immunological methods.
[125] C. Klein,et al. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis , 2016, Molecular Cancer Therapeutics.
[126] R. Larson,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.
[127] James R. Apgar,et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer , 2016, Antibodies.
[128] M. Little,et al. Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding , 1999, FEBS letters.
[129] S. Dübel,et al. Single chain Fab (scFab) fragment , 2007, BMC biotechnology.
[130] G. Denardo,et al. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. , 2001, Cancer biotherapy & radiopharmaceuticals.
[131] Meir Glick,et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. , 2003, Protein engineering.
[132] P. Parren,et al. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. , 2000, Journal of immunology.
[133] Leonard G Presta,et al. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. , 2006, Advanced drug delivery reviews.
[134] S. Muyldermans,et al. Single-domain antibodies as building blocks for novel therapeutics. , 2008, Current opinion in pharmacology.
[135] Lena Shirinian,et al. Structural characterization of a human Fc fragment engineered for lack of effector functions , 2008, Acta crystallographica. Section D, Biological crystallography.
[136] C. Klein,et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors , 2016, Clinical Cancer Research.
[137] T. Ghayur,et al. Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities , 2015, PloS one.
[138] L. Cavacini,et al. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition , 2016, Journal of immunology research.
[139] G. Riethmüller. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. , 2012, Cancer immunity.
[140] M. Soloviev,et al. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. , 2012, Archives of biochemistry and biophysics.
[141] T. D. de Gruijl,et al. Bispecific antibody platforms for cancer immunotherapy. , 2014, Critical reviews in oncology/hematology.
[142] D. Vallera,et al. A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma , 2005, Clinical Cancer Research.
[143] J. Andersen,et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. , 2013, Protein engineering, design & selection : PEDS.
[144] G. Farrington,et al. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. , 2014, Advances in pharmacology.
[145] T. Ghayur,et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) molecule that specifically and potently neutralizes both IL-1α and IL-1β , 2015, mAbs.
[146] Lawren C. Wu,et al. Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.
[147] A. C. Cuello,et al. [17] Bispecific monoclonal antibodies from hybrid hybridomas , 1986 .
[148] E. Padlan,et al. Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. , 1999, Molecular immunology.
[149] V. Roschke,et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis , 2012, mAbs.
[150] D. Goldenberg,et al. The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. , 2012, Bioconjugate chemistry.
[151] U. Brinkmann,et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.
[152] Brian Kuhlman,et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity , 2015, mAbs.
[153] C. Obinger,et al. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast , 2012, Biochimica et biophysica acta.
[154] D. Ellerman,et al. Generation of Bispecific Antibodies by Chemical Conjugation , 2011 .
[155] M. Wittekind,et al. Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.
[156] B. Shen,et al. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. , 2005, Journal of immunological methods.
[157] D. Hicklin,et al. A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.
[158] A. Thakur,et al. Cancer therapy with bispecific antibodies: Clinical experience. , 2010, Current opinion in molecular therapeutics.
[159] H. Kettenberger,et al. Developability assessment during the selection of novel therapeutic antibodies. , 2015, Journal of pharmaceutical sciences.
[160] A. Lugovskoy,et al. Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity , 2010, The Journal of Biological Chemistry.
[161] C. Sentman,et al. Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.
[162] T. Igawa,et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.
[163] A. Plückthun,et al. The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies , 1998, FEBS letters.
[164] C. Klein,et al. A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties* , 2014, The Journal of Biological Chemistry.
[165] R. Stafford,et al. Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system , 2014, mAbs.
[166] Saileta Prabhu,et al. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? , 2012, Expert opinion on drug metabolism & toxicology.
[167] P. Chames,et al. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? , 2009, mAbs.
[168] I. Tomlinson,et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. , 2007, The Journal of infectious diseases.
[169] G. Fey,et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. , 2011, Cancer letters.
[170] M. Muda,et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. , 2011, Protein engineering, design & selection : PEDS.
[171] William McBride,et al. Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells , 2005, Clinical Cancer Research.
[172] G. V. Vande Woude,et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.
[173] A. Jimeno,et al. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors , 2015, Clinical Cancer Research.
[174] R. Williams,et al. Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.
[175] M. Mack,et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[176] B. '. ’t Hart,et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis , 2015, Arthritis Research & Therapy.
[177] B. Jakobsen,et al. Molecular Immunology , 2015 .
[178] G. Himmler,et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. , 2010, Protein engineering, design & selection : PEDS.
[179] C. Klein,et al. Bispecific antibody derivatives based on full-length IgG formats. , 2012, Methods in molecular biology.
[180] V. Zoete,et al. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies , 2016, The Journal of Immunology.
[181] Christopher M. Summa,et al. Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates , 2012, PloS one.
[182] P. Lang,et al. A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells , 2008, Journal of immunotherapy.
[183] R. Kontermann,et al. Bispecific Single-Chain Diabody-Mediated Killing of Endoglin-Positive Endothelial Cells by Cytotoxic T Lymphocytes , 2004, Journal of immunotherapy.
[184] M. Little,et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. , 1999, Journal of molecular biology.
[185] Guy Georges,et al. The emerging role of new protein scaffold-based agents for treatment of cancer. , 2013, Cancer genomics & proteomics.
[186] M. Unno,et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. , 2011, Oncology reports.
[187] Gary L Gilliland,et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. , 2014, Methods.
[188] Jihong Wang,et al. Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.
[189] D. Sblattero,et al. Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation , 2015, Arthritis & rheumatology.
[190] M. Little,et al. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. , 2003, Journal of molecular biology.
[191] B. Carragher,et al. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen , 2013, mAbs.
[192] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[193] P. Kufer,et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.
[194] Chien-Hsing Chang,et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. , 2008, Blood.
[195] A. C. Cuello,et al. Hybrid hybridomas and their use in immunohistochemistry , 1983, Nature.
[196] C. Jakob,et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design , 2011, mAbs.
[197] R. Kontermann,et al. Bispecific Antibodies for Cancer Immunotherapy , 2010, BioDrugs.
[198] W. Mcbride,et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. , 2008, Cancer research.
[199] A. Ebens,et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. , 2014, Cancer research.
[200] M. Little,et al. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. , 2004, Protein engineering, design & selection : PEDS.
[201] E. Wolf,et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[202] K Dane Wittrup,et al. A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.
[203] U. Brinkmann,et al. TriFabs—Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery , 2015, International journal of molecular sciences.
[204] T. Igawa,et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. , 2010, Protein engineering, design & selection : PEDS.
[205] Andrew D. Tustian,et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys , 2015, Scientific Reports.
[206] Dan Lu,et al. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. , 2004, Biochemical and biophysical research communications.
[207] M. Little,et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. , 2000, Cancer research.
[208] R. Kontermann,et al. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. , 2012, Protein engineering, design & selection : PEDS.
[209] W. Richards,et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair , 2016, Nature Communications.
[210] Yong-Sung Kim,et al. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening , 2015, PloS one.
[211] J. Tso,et al. Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.
[212] R. Kontermann,et al. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA‐expressing tumour cells: a comparative analysis of bacterially expressed single‐chain diabody and tandem scFv , 2004, The journal of gene medicine.
[213] R. Kontermann,et al. Dual targeting strategies with bispecific antibodies , 2012, mAbs.
[214] B. Kuhlman,et al. Computationally Designed Bispecific Antibodies using Negative State Repertoires. , 2016, Structure.
[215] V. Streltsov,et al. Dimerisation strategies for shark IgNAR single domain antibody fragments. , 2006, Journal of immunological methods.
[216] P. Carter,et al. Bispecific human IgG by design. , 2001, Journal of immunological methods.
[217] A. Lawson,et al. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding , 2016, mAbs.
[218] A. Nisonoff,et al. Recombination of a mixture of univalent antibody fragments of different specificity. , 1961, Archives of biochemistry and biophysics.
[219] P. Bohlen,et al. Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.
[220] M. Moser,et al. Production and characterization of bispecific single-chain antibody fragments. , 1995, Molecular immunology.
[221] D. Goldenberg,et al. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. , 2010, Blood.
[222] Vincent Larraillet,et al. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor* , 2015, The Journal of Biological Chemistry.
[223] M. Harmsen,et al. Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. , 2008, Veterinary microbiology.
[224] Matthew J. Newman,et al. A review of blinatumomab, a novel immunotherapy , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[225] Jack Bevers,et al. Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines* , 2013, The Journal of Biological Chemistry.
[226] D. Saul,et al. A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting , 2010, British journal of haematology.
[227] Vladimir I Razinkov,et al. Accelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities , 2015, Journal of biomolecular screening.
[228] J. Wells,et al. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.
[229] W. Mcbride,et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[230] A. Kortt,et al. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. , 1996, Molecular immunology.
[231] S. Morrison,et al. Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.
[232] R. Ober,et al. Antibody targeting of HER2/HER3 signaling overcomes heregulin‐induced resistance to PI3K inhibition in prostate cancer , 2015, International journal of cancer.
[233] Rutilio H. Clark,et al. A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism* , 2015, The Journal of Biological Chemistry.
[234] G. Ehninger,et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. , 2011, Molecular immunology.
[235] Andrew D. Tustian,et al. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity , 2016, mAbs.
[236] K. Garber. Bispecific antibodies rise again , 2014, Nature Reviews Drug Discovery.
[237] A. Plückthun,et al. A dimeric bispecific miniantibody combines two specificities with avidity , 1998, FEBS letters.
[238] E. Voss,et al. Construction, expression, and activity of a bivalent bispecific single-chain antibody. , 1994, The Journal of biological chemistry.
[239] J. Huston,et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.
[240] L. Wyns,et al. Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs* , 2001, The Journal of Biological Chemistry.
[241] D. Mould,et al. Drug Development of Therapeutic Monoclonal Antibodies , 2016, BioDrugs.
[242] Gillian Dekkers,et al. IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..
[243] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[244] J. Reichert,et al. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA , 2012, mAbs.
[245] Peter Bohlen,et al. Di-diabody: a novel tetravalent bispecific antibody molecule by design. , 2003, Journal of immunological methods.
[246] Yong-Sung Kim,et al. A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity , 2013, Molecular Cancer Therapeutics.
[247] D. Saul,et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting , 2011, mAbs.
[248] Andrew Leaver-Fay,et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.
[249] RolandEKONTERMANN. Recombinant bispecific antibodies for cancer therapy , 2005 .
[250] D. Allen,et al. Enzyme immunoassays using bispecific diabodies. , 1997, Immunotechnology : an international journal of immunological engineering.
[251] R. Kontermann,et al. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. , 2001, Protein engineering.
[252] A. Kortt,et al. High avidity scFv multimers; diabodies and triabodies. , 1999, Journal of immunological methods.
[253] M. Unno,et al. Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells* , 2007, Journal of Biological Chemistry.
[254] G. Winter,et al. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. , 1997, Protein engineering.
[255] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[256] W. Fiers,et al. Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1 , 2000, The Journal of Immunology.
[257] Scott R. Presnell,et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. , 2009, Protein engineering, design & selection : PEDS.
[258] U. Brinkmann,et al. Quantification of cell surface proteins with bispecific antibodies , 2013, Protein engineering, design & selection : PEDS.
[259] J. Grooten,et al. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. , 2001, Biomolecular engineering.
[260] C. Klein,et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties , 2012, Protein engineering, design & selection : PEDS.
[261] U. Brinkmann,et al. Tumor-antigen-binding bispecific antibodies for cancer treatment. , 2014, Seminars in oncology.
[262] R. Majeti,et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.
[263] K. Nogami. Bispecific antibody mimicking factor VIII. , 2016, Thrombosis research.
[264] P. Parren,et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, mAbs.
[265] Herren Wu,et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. , 2009, Journal of molecular biology.
[266] R. Lerner,et al. Combinatorial surrobody libraries , 2008, Proceedings of the National Academy of Sciences.
[267] Thomas Jostock,et al. Oligomeric forms of single chain immunoglobulin (scIgG) , 2010, mAbs.
[268] Michael J. Gramer,et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, Proceedings of the National Academy of Sciences.
[269] G. A. Lazar,et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens , 2011, mAbs.
[270] R. Lerner,et al. Chemical generation of bispecific antibodies , 2010, Proceedings of the National Academy of Sciences.
[271] Y. Cao,et al. Bispecific antibodies as novel bioconjugates. , 1998, Bioconjugate chemistry.
[272] F. Rüker,et al. Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds , 2012, PloS one.
[273] G. Winter,et al. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). , 1995, Journal of molecular biology.
[274] Zhi Yang,et al. Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker. , 2004, Gynecologic oncology.
[275] B. Bast,et al. Clinical perspectives of bispecific antibodies in cancer , 1997, Cancer Immunology, Immunotherapy.
[276] N. Cheung,et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody , 2015, Oncoimmunology.
[277] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[278] H. Liao,et al. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. , 2015, The Journal of clinical investigation.
[279] W. Mcbride,et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. , 2010, Seminars in nuclear medicine.
[280] D. Segal,et al. Alternative triggering molecules and single chain bispecific antibodies. , 1995, Journal of hematotherapy.
[281] A. Lugovskoy,et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .
[282] Tilman Schlothauer,et al. Functional assessment of antibody oxidation by native mass spectrometry , 2015, mAbs.
[283] J. T. Koerber,et al. An improved single-chain Fab platform for efficient display and recombinant expression. , 2015, Journal of molecular biology.
[284] L. Presta,et al. Design, Construction, and In Vitro Analyses of Multivalent Antibodies , 2003, The Journal of Immunology.
[285] Qing-hui Zhou,et al. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. , 2010, Molecular pharmaceutics.
[286] Wolfgang Schaefer,et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies , 2012, mAbs.
[287] Diego Ellerman,et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.
[288] I. Pastan,et al. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[289] Andrew Burnette,et al. Monoclonal antibody therapeutics with up to five specificities , 2013, mAbs.
[290] Christopher B. Howard,et al. Nanocell targeting using engineered bispecific antibodies , 2014, mAbs.
[291] H. P. Fell,et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. , 1994, Therapeutic immunology.
[292] W. McBride,et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[293] Andreas Wolf,et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.
[294] Nadja Alt,et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. , 2016, Biologicals : journal of the International Association of Biological Standardization.